Post-earnings recap
Reported
Thu, May 11, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CRISPR Therapeutics reported a loss per share of $0.54, which may have contributed to the stock's decline of 1.35% following the earnings announcement. The lack of revenue details and future guidance leaves investors uncertain about the company's short-term performance. The focus on R&D suggests that management is prioritizing long-term growth over immediate financial metrics.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized the importance of ongoing research and development. They did not provide specific updates on future financial expectations.
Management did not provide specific guidance for future quarters.
The focus remains on advancing their pipeline of therapies.